Eculizumab in Acute Motor Axonal Neuropathy: An Ethical Application of an Off-Label Indication
Related Articles
Off-hour effect is not significant in endovascular treatment for anterior circulation large vessel occlusion in a multicentre registry
Background and purpose Whether the off-hour effect has an impact on workflow and outcomes of endovascular treatment (EVT) for anterior circulation large vessel occlusion (AC-LVO)…
Guidelines for Conducting Ethical Artificial Intelligence Research in Neurology: A Systematic Approach for Clinicians and Researchers
Preemptive recognition of the ethical implications of study design and algorithm choices in artificial intelligence (AI) research is an important but challenging process. AI applications…
Eculizumab versus rituximab in generalised myasthenia gravis
Objective Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse.…
Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage
Background and Objectives To investigate whether white matter lesion activity, acute axonal damage, and axonal density in MS associate with CSF neurofilament light chain (NfL)…
Ethical Considerations in Dementia Diagnosis and Care: AAN Position Statement
Alzheimer disease and other dementias present unique practical challenges for patients, their families, clinicians, and health systems. These challenges reflect not only the growing public…
English
العربية
简体中文
Nederlands
Français
Deutsch
Italiano
Português
Русский
Español
Responses